» Articles » PMID: 20459941

Non-alcoholic Fatty Liver Disease (NAFLD) in the Western Cape: a Descriptive Analysis

Overview
Journal S Afr Med J
Specialty General Medicine
Date 2010 May 13
PMID 20459941
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in Western countries, but the disease profile has not yet been described in South Africa. NAFLD affects all spheres of society, especially the poorest and least educated. Aim. To investigate the demographics and clinical and biochemical features of South African patients diagnosed with non-alcoholic fatty liver and non-alcoholic steatohepatitis (NASH) in the Western Cape, South Africa.

Design/method: Overweight/obese subjects were screened by ultrasound and those with fatty liver/hepatomegaly were included. Liver biochemistry, insulin resistance (using the insulin resistance homeostasis model assessment method for insulin resistance, HOMA-IR) and body mass index were assessed and liver biopsies were performed on patients older than 45 years with persistently abnormal liver function and/or hepatomegaly.

Results: We screened 233 patients: 69% coloured, 25% Caucasian, 5% black and 1% Asian. The majority (73%) were female. NAFLD was confirmed histologically in 111 patients, of whom 36% had NASH and 17% advanced liver fibrosis. No black patient had advanced fibrosis. Subjects with NASH had higher mean triglyceride (p=0.03) and cholesterol (p=0.01) levels than subjects with NAFL. All patients were insulin resistant/diabetic. HOMA-IR and not the degree of obesity was strongly associated with advanced fibrosis (p=0.09).

Conclusion: This study is the first to describe the clinical characteristics of NAFLD in South Africa, albeit only in the Western Cape population. Insulin resistance was the universal factor present. The degree of obesity was not associated with severity of disease. The role of genetic risk factors in disease development and severity remains to be defined.

Citing Articles

Non-alcoholic fatty liver disease in Tanzania: prevalence, determinants, and diagnostic performance of triglycerides-glucose index and triglycerides-glucose index -body mass index compared to the hepatic ultrasound in overweight and obese individuals.

Kilonzo S, Kamala E, Jaka H, Ngoya P BMC Gastroenterol. 2024; 24(1):96.

PMID: 38438930 PMC: 10910753. DOI: 10.1186/s12876-024-03164-4.


Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD).

Moghtadaie A, Mahboobi H, Fatemizadeh S, Kamal M EXCLI J. 2023; 22:946-974.

PMID: 38023570 PMC: 10630531. DOI: 10.17179/excli2023-6420.


Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.

Lin H, Zhang X, Li G, Wong G, Wong V J Clin Transl Hepatol. 2021; 9(6):972-982.

PMID: 34966660 PMC: 8666360. DOI: 10.14218/JCTH.2021.00201.


A Matter of Fat: Body Fat Distribution and Cardiometabolic Disease in Africa.

Mahyoodeen N, Crowther N Methods Mol Biol. 2021; 2343:37-56.

PMID: 34473314 DOI: 10.1007/978-1-0716-1558-4_3.


Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally.

Han M, Yu Q, Tafesh Z, Pyrsopoulos N J Clin Transl Hepatol. 2021; 9(1):71-80.

PMID: 33604257 PMC: 7868692. DOI: 10.14218/JCTH.2020.00082.